Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Craig H. Moskowitz, Mariana Bastos-Oreiro, MD PhD, David Ungar, MD, Ilva Dautaj, Matko Kalac, MD PhD

Blood (2019) 134 (Supplement_1): 2807.

https://doi.org/10.1182/blood-2019-128036

Published: 2019

Journal Articles

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT

Matko Kalac, MD PhD, Cristine Candland, RN, Lisa Wallace, RN, Elizabeth Gentner, RN, Shreya Shah, Jennifer E Amengual, MD, Changchun Deng, MD PhD, Suzanne Lentzsch, MD PhD, Owen A. O'Connor, MD PhD, Markus Y Mapara, MD PhD

Blood (2016) 128 (22): 5834.

https://doi.org/10.1182/blood.V128.22.5834.5834

Published: 2016

Journal Articles

Targeting NF-κB with First in Class N-Quinoline Benzenesulfonamides (NQBS) Reveals Potent Activity in Models of Diffuse Large B-Cell Lymphoma (DLBCL)

Matko Kalac, MD PhD, Michael Mangone, PhD, Alison Rinderspacher, PhD, Shi-Xian Deng, PhD, Luigi Scotto, PhD, Jeremie Vendome, PhD, Mukesh Bansal, PhD, Andrea Califano, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 4435.

https://doi.org/10.1182/blood.V126.23.4435.4435

Published: 2015

Journal Articles

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Jennifer E Amengual, MD, Sean Clark-Garvey, Matko Kalac, MD, PhD, Luigi Scotto, PhD, Enrica Marchi, MD, PhD, Celests Rojas, Ellen Neylon, FNP, MSN, RN, OCN, Paul M Johannet, Salvia Jain, MD, Jasmine M. Zain, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2725.

https://doi.org/10.1182/blood.V120.21.2725.2725

Published: 2012

Journal Articles

The Combination of Histone Deacetylase Inhibitors and Hypomethylating Agents Exhibits Marked Synergy In Preclinical Models of T-Cell Lymphoma

Enrica Marchi, MD, Ph, D, Danielle C Bongero, Matko Kalac, MD, PhD, Luigi Scotto, Ph.D., Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 3937.

https://doi.org/10.1182/blood.V116.21.3937.3937

Published: 2010

NARROW

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT

Targeting NF-κB with First in Class N-Quinoline Benzenesulfonamides (NQBS) Reveals Potent Activity in Models of Diffuse Large B-Cell Lymphoma (DLBCL)

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

The Combination of Histone Deacetylase Inhibitors and Hypomethylating Agents Exhibits Marked Synergy In Preclinical Models of T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT

Targeting NF-κB with First in Class N-Quinoline Benzenesulfonamides (NQBS) Reveals Potent Activity in Models of Diffuse Large B-Cell Lymphoma (DLBCL)

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

The Combination of Histone Deacetylase Inhibitors and Hypomethylating Agents Exhibits Marked Synergy In Preclinical Models of T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only